pralsetinib Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 3 (1)

Interventional (1)

Blueprint Medicines Corporation (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadprogressive disease

I am/have/hadrespiratory tract diseases

I am/have/hadcancer treatment

I am/have/hadlung cancer

I am/have/hadcancer therapy

I am/have/hadlung neoplasm

I am/have/hadadenocarcinoma

I am/have/hadneoplasms by site

I am/have/hadchemoradiotherapy

I am/have/hadstage iv non-small cell lung cancer

I am/have/hadmetastatic cancer

I am/have/hadmeasurable disease

I am/have/hadlung disease

I am/have/hadcarcinoma

I am/have/hadnon-small cell lung cancer

I am/have/hadcancer

I am/have/hadmetastatic non-small cell lung cancer

I am/have/hadpulmonary disease

I am/have/hadcancer chemotherapy

I am/have/hadhead and neck neoplasms

added new label for I am/have/had

more

I am looking for

I am looking forimmunomodulators

I am looking forret inhibitor

I am looking forimmunostimulants

I am looking forpralsetinib

I am looking forpembrolizumab

I am looking forpemetrexed

I am looking forgemcitabine

I am looking forplatinum-based chemotherapy

I am looking forcisplatin

I am looking foradjuvant

I am looking forcarboplatin

I am looking forimmunomodulator

I am looking formet inhibitor

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 3
For Seniors
For adults
Recruiting in 100s
Interventional Study
all
Endocrinology
Recruiting

AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive Metastatic NSCLC

Patients who have centrally confirmed progressive disease on the control arm have the option to crossover to pralsetinib.

respiratory tract diseases

progressive disease

immunomodulators

cancer therapy

lung neoplasm

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2024 All rights reserved.